{"id":10869,"date":"2020-11-09T11:53:35","date_gmt":"2020-11-09T17:53:35","guid":{"rendered":"https:\/\/saluddigital.com\/?p=10869"},"modified":"2025-10-21T14:16:53","modified_gmt":"2025-10-21T20:16:53","slug":"ibm-desarrolla-herramienta-basada-en-inteligencia-artificial-para-predecir-alzheimer-antes-de-su-desarrollo","status":"publish","type":"post","link":"https:\/\/saluddigital.com\/en\/plataformas-digitales\/ibm-desarrolla-herramienta-basada-en-inteligencia-artificial-para-predecir-alzheimer-antes-de-su-desarrollo\/","title":{"rendered":"IBM develops Artificial Intelligence-based tool to predict Alzheimer's before it develops"},"content":{"rendered":"
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

For this Artificial Intelligence (AI) model, IBM and Pfizer have developed an algorithm that, through noninvasive speech tests, can predict a potential onset of Alzheimer's in healthy people.<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

This technology boasts an accuracy of 0.7 and an AUC (area under the curve), of 0.74. These results arose from an analysis of data samples from a group of healthy people. According to IBM information, its algorithm represents 59% higher accuracy in predictions based on clinical scales and 50% more than random choice.<\/p>

This model performs natural language processing for analysis of speech samples approximately one to two minutes that are applied through a clinically administered cognitive test.<\/p>

The data samples were provided by Framingham Heart Study, a non-profit organization engaged in heart disease research. Since 1948 they have been able to conduct a long-term study to assess the health of at least 5,000 patients.<\/p><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/section>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

IBM expects the final results of the research to result in benefits in creating a simple and accessible metric for doctors who assess the risk of the disease at its earliest levels. Ultimately, we hope that this research can lead to the development of a simple, direct and accessible metric to help doctors assess the risk of Alzheimer's disease in an individual, leading to earlier intervention.<\/p>

Researchers involved in the project consider that the research has particularities and differences marked in relation to current Research on Alzheimer's.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

The data used correspond to cognitively healthy patients, unlike other studies that predict the future onset of neurological diseases with patients who already show signs of cognitive decline. The study is also focused on the risk assessment of disease in the general population, unlike other studies that focus their research on high-risk groups, with a genetic history.<\/p>

\u201cUltimately, we hope this research can lead to the development of a simple, straightforward and accessible metric to help clinicians assess the risk of Alzheimer\u2019s disease in an individual, leading to earlier intervention\u201d, mentions the IBM article.<\/p>

Several studies have been published through this research by IBM and Pfizer, in important scientific journals such as Nature<\/em> and The New England Journal of Medicine<\/em>. \u201cOur vision is that one day clinicians will have multiple AI and machine learning tools to help identify if an individual is at risk of developing Alzheimer\u2019s disease.\u201d<\/p><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/section>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t BIBLIOGRAPHY <\/a>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t

IBM<\/strong><\/p>

https:\/\/www.ibm.com\/blogs\/research\/2020\/10\/ai-predict-alzheimers\/<\/a><\/p><\/div><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"

Para este modelo de Inteligencia Artificial (IA), IBM y Pfizer han desarrollado un algoritmo que, a trav\u00e9s de pruebas de habla no invasivas, puede predecir una potencial aparici\u00f3n de Alzheimer en personas sanas. Esta tecnolog\u00eda presume tener una precisi\u00f3n de 0.7 y un AUC (\u00e1rea bajo la curva), de 0.74. Dichos resultados surgieron gracias a un an\u00e1lisis de muestras de datos de un grupo de personas sanas. Seg\u00fan informaci\u00f3n de IBM, su algoritmo representa un 59% de mayor precisi\u00f3n en las predicciones basadas en escalas cl\u00ednicas y 50% m\u00e1s que la elecci\u00f3n aleatoria. Este modelo realiza el procesamiento del lenguaje natural para el an\u00e1lisis de muestras de habla de uno a dos minutos aproximadamente que se aplican a trav\u00e9s de una prueba cognitiva administrada cl\u00ednicamente. Las muestras de datos fueron proporcionadas por Framingham Heart Study, una organizaci\u00f3n sin fines de lucro que se dedica a la investigaci\u00f3n sobre enfermedades del coraz\u00f3n. Desde 1948 lograron realizar un estudio de larga duraci\u00f3n para evaluar la salud de al menos 5 mil pacientes. IBM espera que los resultados finales de la investigaci\u00f3n resulten en beneficios para la creaci\u00f3n de una m\u00e9trica sencilla y accesible para los m\u00e9dicos que eval\u00faan el riesgo de la enfermedad en sus niveles tempranos. En \u00faltima instancia, esperamos que esta investigaci\u00f3n pueda conducir al desarrollo de una m\u00e9trica simple, directa y accesible para ayudar a los m\u00e9dicos a evaluar el riesgo de la enfermedad de Alzheimer en un individuo, lo que lleva a una intervenci\u00f3n m\u00e1s temprana. Los investigadores que participan en el proyecto consideran que la investigaci\u00f3n tiene particularidades y diferencias marcadas en relaci\u00f3n a las investigaciones actuales sobre Alzheimer. Los datos utilizados corresponden a pacientes cognitivamente sanos, a diferencia de otros estudios que predicen la aparici\u00f3n futura de enfermedades neurol\u00f3gicas con pacientes que ya muestran signos de deterioro cognitivo. El estudio est\u00e1 enfocado tambi\u00e9n en la evaluaci\u00f3n de riesgo de enfermedad en poblaci\u00f3n general, a diferencia de otros estudios que se centran su investigaci\u00f3n en grupos de alto riesgo, con antecedentes gen\u00e9ticos. \u201cEn \u00faltima instancia, esperamos que esta investigaci\u00f3n arraigue y ayude en el futuro desarrollo de una herramienta simple, directa y de f\u00e1cil acceso para ayudar a los m\u00e9dicos a evaluar el riesgo de un paciente de enfermedad de Alzheimer a trav\u00e9s del an\u00e1lisis del habla y el lenguaje, y en conjunto con una serie de otras facetas de la salud y la biometr\u00eda de un individuo\u201d, menciona el art\u00edculo de IBM. Diversos estudios han sido publicados a trav\u00e9s de esta investigaci\u00f3n de IBM y Pfizer, en importantes revistas cient\u00edficas como Nature y The New England Journal of Medicine. \u201cNuestra visi\u00f3n es que alg\u00fan d\u00eda los m\u00e9dicos tengan m\u00faltiples herramientas de aprendizaje autom\u00e1tico e inteligencia artificial para ayudar a identificar si una persona est\u00e1 en riesgo de desarrollar la enfermedad de Alzheimer\u201d. BIBLIOGRAF\u00cdA IBM https:\/\/www.ibm.com\/blogs\/research\/2020\/10\/ai-predict-alzheimers\/<\/p>","protected":false},"author":1,"featured_media":10867,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[156,153],"tags":[145],"class_list":["post-10869","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-big-data","category-plataformas-digitales","tag-noticias"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/saluddigital.com\/en\/wp-json\/wp\/v2\/posts\/10869","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/saluddigital.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/saluddigital.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/saluddigital.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/saluddigital.com\/en\/wp-json\/wp\/v2\/comments?post=10869"}],"version-history":[{"count":0,"href":"https:\/\/saluddigital.com\/en\/wp-json\/wp\/v2\/posts\/10869\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/saluddigital.com\/en\/wp-json\/wp\/v2\/media\/10867"}],"wp:attachment":[{"href":"https:\/\/saluddigital.com\/en\/wp-json\/wp\/v2\/media?parent=10869"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/saluddigital.com\/en\/wp-json\/wp\/v2\/categories?post=10869"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/saluddigital.com\/en\/wp-json\/wp\/v2\/tags?post=10869"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}